like gener franchis mani undifferenti acquisit
made cover constant downward deterior base busi addit
upjohn simpli larger merger solv noth
neg view like increas close believ quarter continu
confirm thesi
rev reach y/i ep y/i street
expect earn due lower spend discuss
stand alon well upjohn expect would note besid
fact revenu essenti flat y/i adjust free cash flow
vs investor find alarm
stand alon guidanc manag chosen widen origin
view provid juli time upjohn announc
forecast revenu rang previous recal
stand alon guidanc low-end like essenti flat
level adjust ebitda target also widen
forecast midpoint flat
around level assum adjust
free cash flow also flat y/i would essenti level five
year ago
lack cash gener last year despit signific inorgan
invest compani product acquisit like brought
ebitda along recent launch new product
combin acquisit new launch abl grow busi
fact bare allow maintain current annual cash gener level
window view basic metric demonstr underli wealth
destruct believ upjohn join potenti acceler certainli
solv
addit manag appear signal thing could actual get wors
confus commentari potenti combin revenu around
take recent upjohn revenu expect roughli would mean
seriou deceler somewher recal origin august guidanc
combin entiti pro forma rev reach ebitda
take consider commentari today call would appear
estim like meaning lower model chang lower dcf
mean combin one entiti stagnating/declin
one entiti upjohn rapidli deterior point manag appear
alreadi unsur busi base
pleas see page report import disclosur
continu view roughli flat cash gener last year guid
year good marker health lack thereof busi analysi
see share repurchas line alter note rel
unchang cash gener net capit expenditur observ last
year project manag despit spent
acquisit ad roughli ebitda continu believ long-
term investor better wealth creat altern exist reiter market perform
 potenti restasi approv
advair copaxon neulasta hope
stabl execut
potenti greater consist
approv differenti product
lack meaning gener
approv off-set baselin deterior
continu lack bad decis
make busi develop front
global gener specialti pharmaceut compani
interestingli pfizer call manag increas anticip upjohn
estim includ meridien japan divis increas upjohn
revenu roughli low high end reflect inclus
divis rang previous howev bit
surpris littl inclus addit revenu divis
ebitda appear move upjohn ebitda guidanc
believ modest ebitda increas like
due core busi pricing/margin degrad gener entir upjohn
franchis similar issu one core theme would
invest combin entiti unclear whether abl negoti
busi ad combin entiti compound
difficult situat pro-forma entiti find
although look relitig recent histori believ
necessari understand compani better understand
go upjohn stand-alone critic take-away
perform underlin thesi busi model
system declin mani argu new entiti find better posit
stand-alone unsur right question even
unsur whether statement even accur given continu appear
senior manag firmli control
underscor point long felt stand-alone absolut broken
believ rather fix problem upjohn busi like
compound note adjust free cash flow reach
dramat versu essenti level
roughli four year ago guidanc anticip stand-alone
revenu guidanc ebitda expect appear also anoth
flat year stand-alone cash gener deterior adjust free cash flow
last year despit tremend invest toward
compani product acquisit yet despit roughli spent
ebitda purchas total busi like gener addit
cash even launch copaxon neulasta advair
other ad approv provid
relief alter system problem inher gener model
rare see system wealth destroy mess
combin upjohn busi certainli significantli higher near-
term cash flow leverag improv move stand-alone
roughli newco despit combin debt escal roughli pro
forma indic destroy tremend valu last
year like bleed ebitda rush replac via acquisit
new product launch believ combin entiti suffer fate
deterior line global basi dramat pain
continu larger entiti major sell point busi
de-lever fast worri make capit alloc decis
would invest inde appear senior manag
still control caus concern regardless alloc cash
flow direct dividend addit whenev hear strateg valu
futur growth predic china also caus us paus given constant
uncertainti market evidenc recent trend
cowen compani
upjohn mylan includ gener brand includ epipen total combin upjohn/ gross gross margin gross margin upjohn margin oper upjohn guid synergi incom interest interest roughli total debt upjohn transact interest interest expens upjohn transact incom tax rate mylan tax rate guidanc incom tax rate tax rate upjohn tax ratenet incom net epsep oper share fulli dilut includ share upjohn transact sharehold an/upjohn pro-forma estim annual build-up mm cowen
cowen compani
assumpt output increas share outstand specul debt pfizerenterpris gross margin oper tax increas capital-expenditure work free net debt gener ratio exit upjohn dcf cowen
cowen compani
salestot north american gener includ gener brand includ epipen meda key driver meda key driver total pharmaceut balanc throughout portfolio mylan//meda balanc contributor margin good spend control combin compani gener synergi realiz interest expens debt via roughli total debt assum debt paydown meda transact interest interest expens gains/loss matrix minor interestnon-oper mylan tax rate guidanc rate incom net net epsep oper valuat year share fulli dilut includ share assum meda transactionmylan lab estim annual build-up mm cowen
valuat methodolog arriv fair valu util discount cash flow dcf
approach addit assum busi develop deriv price
risk includ grow competit dynam specialti pharmaceut space
abil manag execut extern growth success acquir
new strateg accret product abil grow organ keep product
pipelin robust potenti regulatori delay reject failur pipelin product
econom sensit self-pay product weaken consum demand domest
intern price pressur market product failur execut new
gener believ risk respect manag abil execut
organ growth next year risk compani specialti busi come
increas competit epipen gener busi potenti delay lack
approv key product risk upsid includ approv gener advair
yet factor and/or greater contribut copaxon current model
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock mylan lab bausch health compani horizon pharma secur
cowen compani llc manag co-manag public offer horizon pharma past month
cowen compani llc receiv compens invest bank servic horizon pharma past month
horizon pharma past month client cowen compani llc cowen compani llc provid provid invest bank servic
past month
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
